Statute Details
- Title: Medicines (Medical Advertisements) Regulations
- Act Code: MA1975-RG2
- Legislative Type: Subsidiary legislation (SL)
- Authorising Act: Medicines Act (Chapter 176), Sections 52 and 74
- Citation: Rg 2, G.N. No. S 289/1977; Revised Edition 2000 (31 Jan 2000)
- Status: Current version as at 27 Mar 2026
- Key Regulations: Regulation 2 (definitions); Regulation 3 (permit requirement); Regulation 4 (application); Regulation 5 (validity); Regulation 6 (terms/conditions); Regulation 7 (refusal/suspension/revocation); Regulation 8 (duty of printer/publisher); Regulation 10–11 (exceptions); Regulation 12 (permit number); Regulation 13 (alteration/amendment); Regulation 13A (transfer of permit); Regulation 14 (fees); Regulation 15 (penalty)
- Schedule: Fees
What Is This Legislation About?
The Medicines (Medical Advertisements) Regulations (“the Regulations”) create a licensing and compliance framework for advertising medicinal products in Singapore. In plain terms, they require most “medical advertisements” and related “sales promotions” to be approved by the licensing authority before they are issued or conducted. The Regulations are designed to control the content, distribution, and commercial promotion of medicines to reduce misleading claims and protect public health.
The Regulations sit alongside the Medicines Act and operate as a gatekeeping mechanism. They do not attempt to regulate every form of communication about medicines; instead, they focus on advertisements and promotional activities that reach the public or otherwise fall within the definition of “medical advertisement” and “sales promotion”. They also impose obligations on intermediaries—such as printers and publishers—so that the approval requirement is not circumvented through third-party publication.
For practitioners, the practical takeaway is that pharmaceutical marketing is not “free-form” in Singapore. If a communication qualifies as a medical advertisement or sales promotion, the advertiser and the publisher must ensure a valid permit exists, the permit number is displayed, and the advertisement is not altered without approval. Non-compliance can lead to criminal liability.
What Are the Key Provisions?
1) The core permit requirement (Regulation 3)
Regulation 3 provides the central rule: except as provided in the Regulations, no person shall issue (or cause to be issued) any “medical advertisement” or conduct any “sales promotion” without first obtaining a permit from the licensing authority. This is the legal “trigger” for compliance. If the activity falls within the definitions, the permit is a condition precedent to publication or promotion.
2) Definitions that shape the scope (Regulation 2)
The Regulations define “medical advertisement” and “sales promotion”. “Medical advertisement” means any advertisement of a medicinal product, but it excludes certain advertisements referenced in the Medicines Act (section 51(1)(a) or (b) or (2)). This carve-out matters: not every mention of a medicine necessarily becomes a regulated “medical advertisement”.
“Sales promotion” is defined broadly to include sales campaigns (including door-to-door sales and price discounts), exhibitions, competitions, and any other activity meant to introduce, publicise or raise the profile, public awareness or visibility of the medicinal product. This breadth means that promotional tactics beyond traditional print/online ads—such as events, contests, and discount-driven campaigns—can still require a permit.
3) Application, validity, and conditions (Regulations 4–6)
An application for a permit (or renewal) must be in the form required by the licensing authority (Regulation 4). Permits are generally valid for one year from the date granted unless sooner revoked (Regulation 5).
Importantly, Regulation 6 allows the licensing authority to grant a permit subject to such terms and conditions as it thinks fit. In practice, this means the permit may impose content requirements, formatting requirements, limitations on claims, or other compliance obligations. Lawyers advising marketing teams should treat the permit conditions as legally binding constraints on what can be published.
4) Enforcement through refusal, suspension, revocation, and appeal (Regulation 7)
Regulation 7 empowers the licensing authority to refuse a permit or suspend or revoke an existing permit without assigning any reason. This is a significant enforcement lever: the absence of a duty to give reasons can affect how applicants structure submissions and manage risk.
If a person is aggrieved, they may appeal to the Minister whose decision is final. This finality underscores the importance of getting the application right at the outset and ensuring that supporting documentation and proposed content align with regulatory expectations.
5) Duties of printers and publishers (Regulation 8)
Regulation 8 imposes a compliance duty on those who print or publish. No person shall print or publish (or cause to be printed or published) any medical advertisement that is not a sales promotion unless the printer/publisher has ascertained that a permit has been granted for that advertisement. This provision is designed to prevent “papering over” non-compliance by outsourcing printing or publication to third parties.
For counsel, this means that publishers, agencies, and production vendors should implement verification steps (e.g., obtaining the permit number and checking validity) before publication.
6) Exceptions: when the permit requirement does not apply (Regulations 10–11)
Regulation 10 provides an exception where the medical advertisement is directed exclusively at a person who may lawfully sell or supply medicinal products in the course of that person’s trade, business or profession, and is not accessible to the general public. This is a “restricted audience” exception. It is not enough that the advertisement is intended for professionals; it must also not be accessible to the general public. Practically, this raises questions about distribution channels, access controls, and whether the content can be viewed outside the intended professional audience.
Regulation 11 further excludes certain categories: (a) reference advertisements and trade advertisements; and (b) advertisements issued/published by public authorities or persons authorised by the Minister. The definitions of “reference advertisement” and “trade advertisement” are technical and content-specific. For example, a “trade advertisement” in a catalogue or price list may be excluded if it does not contain recommendations relating to use other than as part of the medicinal product’s name or therapeutic classification heading/sub-heading.
7) Permit number display (Regulation 12)
Any person who issues or publishes a medical advertisement (including conducting a sales promotion) must ensure that the permit number is displayed on, or on material accompanying, the advertisement in accordance with terms and conditions specified in the permit. This is a transparency requirement. It also provides a practical compliance check for regulators and for downstream parties (e.g., publishers) to verify that the advertisement is properly authorised.
8) Alterations and amendments require approval (Regulation 13)
A person must not alter or amend the contents of a medical advertisement for which a permit has been granted unless (a) an application is made in the form required to amend the permit to reflect the alteration/amendment, and (b) the licensing authority approves the application. This is critical in real-world marketing workflows where copy is revised, design elements are adjusted, or claims are updated. Even seemingly minor changes may be treated as “alterations” requiring an amendment application.
9) Transfer of permits (Regulation 13A)
A permit cannot be transferred unless the person makes an application in the required form to transfer the permit to another person and the licensing authority approves it. This provision is particularly relevant in corporate restructuring, outsourcing arrangements, or when marketing rights move between entities. Counsel should ensure that any change in the responsible entity is handled through the formal transfer process rather than informal reassignment.
10) Fees and no refunds (Regulation 14 and Schedule)
Regulation 14 sets out that fees are payable for applications for permits, permits/renewals, applications to amend permits, and applications to transfer one or more permits. The exact amounts are specified in the Schedule. The Regulations also state that no refund shall be made in respect of any fee paid. This affects budgeting and should be factored into compliance planning, especially where multiple amendment submissions are anticipated.
11) Penalty for contraventions (Regulation 15)
Regulation 15 creates criminal liability for contravening or failing to comply with Regulations 3, 8, 12 or 13. On conviction, the offender is liable to a fine not exceeding $5,000, imprisonment for up to 12 months, or both. For legal risk management, this is a clear signal that the permit requirement, printer/publisher verification duty, permit number display, and prohibition on unapproved alterations are treated as serious compliance obligations.
How Is This Legislation Structured?
The Regulations are structured as a set of numbered regulations followed by a Schedule. The numbering reflects a compliance lifecycle:
(1) Definitions (Regulation 2) establish what counts as a “medical advertisement” and “sales promotion”.
(2) Permit process (Regulations 3–7) sets the requirement to obtain a permit, the application form, the one-year validity, the authority’s discretion to impose terms and conditions, and the authority’s power to refuse/suspend/revoke with a final appeal to the Minister.
(3) Publication controls (Regulations 8–13A) impose duties on printers/publishers, provide exceptions, require display of permit numbers, regulate alterations/amendments, and regulate transfer of permits.
(4) Administrative matters (Regulation 14 and the Schedule) cover fees and no refunds.
(5) Offences and penalties (Regulation 15) specify the consequences for key contraventions.
Who Does This Legislation Apply To?
The Regulations apply broadly to “any person” who issues or causes to be issued medical advertisements, conducts sales promotions, prints or publishes advertisements, and those who alter or amend permitted content. This includes manufacturers, suppliers, importers/exporters, marketing agencies, publishers, and printers—any party in the chain of communication.
However, the extent of obligations depends on the role. For example, Regulation 8 specifically targets printers and publishers (with a verification duty for medical advertisements that are not sales promotions). Regulation 10 and 11 provide content and audience-based exceptions, so the same communication may be regulated in one context but exempt in another (e.g., restricted professional audiences versus general public access).
Why Is This Legislation Important?
For practitioners advising pharmaceutical clients, the Regulations are important because they translate regulatory policy into operational requirements. They affect how marketing materials are drafted, reviewed, approved, printed, published, and updated. A common compliance failure in advertising regimes is treating regulatory approval as a one-time event; here, the Regulations require ongoing control through permit validity (one year), amendment approvals for changes, and permit transfer approvals when responsibility shifts.
From an enforcement perspective, the Regulations provide multiple compliance “checkpoints”: the licensing authority’s power to refuse/suspend/revoke (Regulation 7), the duty of printers/publishers to ascertain permits (Regulation 8), the mandatory display of permit numbers (Regulation 12), and the prohibition on unapproved alterations (Regulation 13). These checkpoints reduce the chance that non-compliant content can be published without detection.
Finally, the penalty provision (Regulation 15) creates real deterrence. While the maximum fine and imprisonment terms may appear modest compared to some other regulatory regimes, the existence of criminal liability for contraventions of core provisions means that compliance should be treated as a legal priority rather than a purely administrative matter. In disputes, enforcement actions may also turn on whether the communication qualifies as a “medical advertisement” or “sales promotion”, whether an exception applies, and whether the permit number and amendment approvals were properly handled.
Related Legislation
- Medicines Act (Chapter 176) — authorising provisions (Sections 52 and 74) and referenced exclusions in the definition of “medical advertisement” (Section 51(1)(a), (b) and (2)).
Source Documents
This article provides an overview of the Medicines (Medical Advertisements) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.